The emerging field of precision medicine is speeding ahead, marked by non-traditional new partnerships across different groups in medicine, health care, technology, academia and government. It is increasingly viewed as mainstream treatment, especially in cancer research and diagnostics. Many pharmaceutical, biotechnology and device firms are taking the plunge, looking to precision medicine as a way to improve patient outcomes by reimagining business models that simultaneously reduces the cost but improves the quality of care.